Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin (1-7) for cognitive impairment in heart failure
NCT03159988Phase 2Suspended
- Sponsor
- University of Arizona
- Start
- Apr 2016
- Primary completion
- Jun 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of angiotensin-(1-7) in cognitive impairment, sponsored by University of Arizona. Primary endpoint: Memory Intentions Test at 12 weeks. Started Apr 2016; status: suspended.
02
Drugs
angiotensin-(1-7)
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT03159988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159988.